Today is a happy day for fans of Insulet’s tubeless insulin pump system! The FDA has finally approved the next-generation OmniPod, which is 34% smaller, 25% lighter, and 16% slimmer — yet still holds same 200 units of insulin.
The new design will also feature a “pink slide insert,” that pushes a piece of pink plastic to be visible through a new, second window in the center of the Pod, to “help users verify that…
The diabetes community has long been calling for cheaper, generic glucose test strips that would ideally work with a variety of meter brands. Dream on, right?
In fact, some companies out there are making excellent headway in the “generic” category, despite being under siege by “the big guys.”
One of those is a small Southern California-based company called Pharma Tech Solutions that’s looking to enter the market with a product it’s eager to distribute called the…
We’ve seen the sensational headlines over and over: “no more needles for diabetics!”
Maybe soon we’ll be inhaling insulin through our noses. Or rolling it on like a stick of deodorant. Or lapping it up in the form of a wafer on our tongues.
Maybe we’ll be getting non-stop blood sugar readings just by shining a beam of light onto our skin…
Look out! Here come glucose-sensoring tattoos and saliva measurements that promise pain-free BG…
The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
Last week, thousands of healthcare companies and investors therein descended upon San Francisco for the 2011 JP Morgan Healthcare Conference. Although I wasn’t able to attend personally, I’ve been keeping an eagle eye on what happened there in terms of diabetes through my friend, seasoned industry observer David Kliff of Diabetic Investor — reporting daily on what he calls “the wacky world of diabetes devices.”
He’s kindly given me permission to summarize some of his…